Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Diabetes Obes Metab. 2013 Sep;15(0 3):10.1111/dom.12171. doi: 10.1111/dom.12171

Figure 4. Therapeutic potential of key NAD intermediates against age-associated diseases.

Figure 4

Supplementation of key NAD intermediates, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), improves insulin secretion, insulin action, energy expenditure, and cognitive function and prevents inflammatory reactions in mice. These NAD intermediates are expected to be translatable as effective anti-aging nutriceuticals into humans in the near future.